GLP-1 pen malfunctions: what actually happens to your dose?

What did @bigmama1989k actually say?

She documented her Wegovy auto-injector failing mid-shot and concluded she had received none of the medication from that attempt. Her response: call the manufacturer, try a second pen in her stomach, and keep filming. That is actually a reasonable chain of decisions, even if the confidence behind some of them deserves a closer look.

The core claims here are two: that the pen malfunctioned through no fault of her own, and that she "know[s] for a FACT" she got none of the medicine from the first attempt. The first is plausible and documented in FDA adverse event databases. The second is the part that needs scrutiny, because knowing with certainty whether a dose was delivered is harder than it sounds.

Does the science back this up?

Auto-injector malfunctions are real and documented, not just a TikTok phenomenon. The evidence supports taking them seriously, but it does not support the certainty that zero drug was delivered in a failed injection.

Novo Nordisk's Wegovy FlexTouch pen and similar auto-injector designs have been flagged in FDA MedWatch reports for delivery failures, including incomplete dose release and needle retraction issues. A 2022 review by Bhatt et al. in Diabetes Technology and Therapeutics found that auto-injector usability errors, including incomplete injections, account for a meaningful proportion of real-world dosing failures across injectable biologics. The problem is that a visible malfunction does not automatically confirm a zero-dose delivery. Some portion of the drug can deposit subcutaneously even when the pen appears to fail. Without a plasma semaglutide assay, which nobody is ordering at home, you cannot know with certainty what happened.

What did they get wrong (or right)?

She got the response protocol mostly right. Contacting the manufacturer is the correct first move. Novo Nordisk has a documented replacement process for pen malfunctions, and the FDA encourages MedWatch reporting for device failures. That part deserves genuine credit.

Where the video overshoots is the certainty of a zero dose. Saying she knows "for a FACT" she got none of the medicine is not a clinical statement anyone can make from visual inspection alone. Subcutaneous semaglutide absorption is not visible to the naked eye. If she had received even a partial dose and then injected a full second pen, she may have administered more than the intended dose for that week. That is not trivial. Semaglutide has a roughly one-week half-life, and doubling up increases the risk of nausea, vomiting, and delayed gastric emptying in the short term. To be fair, she was not giving medical advice here, she was documenting her experience. But 11,900 viewers watching this may draw their own conclusions about when a second pen is appropriate.

What should you actually know?

If your pen appears to malfunction, the right call is to contact the manufacturer or pharmacy before automatically re-dosing. That is not a bureaucratic formality. It is how you protect yourself from an accidental double dose and how you get a replacement covered.

Novo Nordisk's customer support line is on the Wegovy packaging and their website. You should also report device failures to FDA MedWatch, because aggregate reports are how regulators identify systemic defects. The decision to inject again should ideally involve your prescriber, not just personal certainty that the first shot did not work. A partial dose is pharmacologically possible even when the pen behaves strangely. Your prescriber can help you weigh whether the GI risk of a potential extra dose outweighs waiting until your next scheduled injection. That conversation is worth a phone call.

Bottom line

This video is more responsible than most GLP-1 content on TikTok. Documenting a malfunction, encouraging others not to panic, and pointing people toward the manufacturer is genuinely useful. The problem is the unqualified certainty about dose delivery, which is not something anyone can confirm at home. The practical advice holds up. The confidence level does not.